GRFS and GRF-P Related Headlines
Go Back- Grifols starts two Phase 3 trials to expand immunoglobulin labels
- Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
- Grifols launches FESILTY fibrinogen concentrate in the US
- Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
- Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
GRFS and GRF-P Related Press Releases
Go Back- Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
- Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
- Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
